Raphael Pharmaceutical (RAPH) Research & Development (2020 - 2024)
Raphael Pharmaceutical (RAPH) posted Research & Development of $211000.0 for Q4 2024, up 30.25% sequentially from $162000.0 in Q3 2024, and up 160.63% YoY from $80957.0 in Q1 2024.
Raphael Pharmaceutical (RAPH) Research & Development (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical has reported Research & Development for 5 years, with the latest figure at $211000.0 in Q4 2024.
- Quarterly Research & Development rose 160.63% year-over-year to $211000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $776000.0 (up 36.38% YoY) and the FY2025 annual result came in at $631000.0, down 18.69% from the prior year.
- Research & Development improved to $211000.0 in Q4 2024 per RAPH's latest filing, from $162000.0 in the prior quarter.
- Over five years, Research & Development peaked at $676000.0 in Q4 2022 and troughed at -$348000.0 in Q4 2023.
- A 5-year average of $207000.0 and a median of $211000.0 in 2024 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 248.81% in 2023, down 151.48% in 2023.
- Over 5 years, Research & Development stood at $220000.0 in 2020, then increased by 1.82% to $224000.0 in 2021, then jumped by 201.79% to $676000.0 in 2022, then sank by 151.48% to -$348000.0 in 2023, then surged by 160.63% to $211000.0 in 2024.
- According to Business Quant data, Research & Development over the past three periods registered $211000.0, $162000.0, and $24000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | 40,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 211,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 24,000.00 |
| Mar 31, 2024 | 379,000.00 |
| Dec 31, 2023 | -348,000.00 |
| Sep 30, 2023 | 510,000.00 |
| Jun 30, 2023 | 293,000.00 |
| Mar 31, 2023 | 114,000.00 |
| Dec 31, 2022 | 676,000.00 |
| Sep 30, 2022 | 332,000.00 |
| Jun 30, 2022 | 84,000.00 |
| Mar 31, 2022 | 86,000.00 |
| Dec 31, 2021 | 224,000.00 |
| Sep 30, 2021 | 161,000.00 |
| Jun 30, 2021 | 222,000.00 |
| Mar 31, 2021 | 169,000.00 |
| Dec 31, 2020 | 220,000.00 |